GLUCOSE LOWERING DRUGS OR STRATEGIES, MAJOR ADVERSE CARDIOVASCULAR EVENTS AND HEART FAILURE OUTCOMES, AND ASSOCIATION WITH WEIGHT LOSS - META-ANALYSIS OF LARGE CARDIOVASCULAR OUTCOME TRIALS

Volume: 35, Issue: 10, Pages: S78 - S78
Published: Oct 1, 2019
Abstract
Glucose-lowering drugs or strategies (GLDS) have varied effects on major adverse cardiovascular events (MACE) and heart failure (HF) in cardiovascular outcomes trials. Mechanisms driving cardiovascular risk reduction remain elusive. We searched Ovid MEDLINE, the Cochrane Central Register of Controlled Trials databases, PubMed, and meeting abstracts up to April 2019 for large CV outcome randomized controlled trials of glucose-lowering drugs or...
Paper Details
Title
GLUCOSE LOWERING DRUGS OR STRATEGIES, MAJOR ADVERSE CARDIOVASCULAR EVENTS AND HEART FAILURE OUTCOMES, AND ASSOCIATION WITH WEIGHT LOSS - META-ANALYSIS OF LARGE CARDIOVASCULAR OUTCOME TRIALS
Published Date
Oct 1, 2019
Volume
35
Issue
10
Pages
S78 - S78
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.